Category: Mercator MedSystems
Mercator MedSystems Receives $11M in Series D Equity Financing Led by Shenzhen Salubris Pharmaceuticals Co.
Capital will fuel continued research and clinical development of micro-infusion platform
EMERYVILLE, Calif., June 21, 2018 /PRNewswire/ — Mercator MedSystems, Inc., today announced it has received $11 million in Series D equity financing led by Shenzhen Salubris Pharmaceuticals Co. (Salubris), with participation from current Mercator investors and other undisclosed new investors. The new funding will further advance the clinical development of Mercator’s proprietary micro-infusion catheter systems and accelerate the company’s vision of improving outcomes in patients around the world with cardiovascular and pulmonary disease.
Mercator Medsystems leaps forward with Bullfrog into LIMBO-ATX trial
BioWorld MedTech, November 1, 2017
Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
First U.S. Trial to Assess Delivery of a -Limus Agent to Prevent BTK Restenosis
EMERYVILLE, Calif., April 26, 2017 /PRNewswire-USNewswire/ — Mercator MedSystems, Inc., a medical technology company, announced today the first patient enrollment into the TANGO (Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee) clinical trial. TANGO will study the effects of using Mercator’s proprietary Bullfrog® Micro-Infusion Device for the adventitial delivery of the drug TORISEL® (temsirolimus) after revascularization of lesions below the knee (BTK) in patients with critical limb ischemia (CLI).
Mercator Bullfrog Device Being Used in New Proteon Therapeutics Study
Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee
WALTHAM, Mass. – November 10, 2016 – Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced the first patient was dosed in a Phase 1 clinical study evaluating a single administration of investigational drug vonapanitase delivered immediately following angioplasty to patients with peripheral artery disease (PAD).
Late-Breaking Clinical Trial Data Presented from Mercator MedSystems’ DANCE Trial at VIVA 2016
First Large-Scale Trial of the Bullfrog Micro-Infusion Device with Dexamethasone Shows Positive Results
EMERYVILLE, Calif., Sept. 21, 2016 /PRNewswire/ — Mercator MedSystems today announced that 13-month data from the DANCE trial was presented during a late-breaking scientific session at the Vascular Interventional Advances (VIVA) Annual Conference 2016 in Las Vegas, Nevada. DANCE is a prospective, multicenter, single-arm study designed to assess the clinical performance of the localized delivery of a generic steroid, dexamethasone, to the tissues around arteries that have been injured during endovascular interventions, using Mercator’s proprietary Bullfrog® Micro-Infusion Device.
LIMBO-ATX Trial Begins in United States
Mercator MedSystems Announces First Patients Enrolled In U.S. Below The Knee (BTK) Clinical Trial In North Carolina And Texas
LIMBO-PTA Trial Begins in Germany
Mercator MedSystems Announces First Patient Enrolled in Below the Knee (BTK) Clinical Trial
EMERYVILLE, Calif., Jan. 21, 2016 – Mercator MedSystems, Inc., has announced their first patient enrollment from Bad Krozingen, Germany, in the company’s LIMBO-PTA clinical trial. This trial combines localized drug delivery using the company’s proprietary Bullfrog® Micro-Infusion Device of an off-the-shelf anti-inflammatory steroid (dexamethasone) with angioplasty. The study measures the benefit of adding drug delivery to the catheter-based re-opening of arteries below the knee in patients suffering from critical limb ischemia (CLI).